busulfan has been researched along with Chronic Disease in 104 studies
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To reduce the incidence of graft-versus-host disease (GVHD), we added Thymoglobulin (THY) to dose-adjusted oral busulfan plus cyclophosphamide (targeted BUCY)." | 9.12 | Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. ( Anasetti, C; Appelbaum, FR; Boeckh, M; Deeg, HJ; Doney, KC; Flowers, ME; Hansen, JA; Heimfeld, S; Kiem, HP; Martin, PJ; McCune, JS; Myerson, D; Nash, RA; O'Donnell, PV; Radich, JP; Sandmaier, BM; Scott, BL; Sorror, ML; Storb, R; Storer, BE; Warren, EH; Witherspoon, RP; Woolfrey, A, 2006) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 7.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| " We reviewed our experience using busulfan and cyclophosphamide (CY), instead of TBI, as the preparative regimen for allogeneic BMT to study the incidence and relationship to graft-versus-host disease (GVHD) of post-treatment eosinophilia." | 7.69 | Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen. ( Bolwell, BJ; Kalaycioglu, ME, 1994) |
| "Clofarabine has potent antileukemia activity and its inclusion in reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT) for acute leukemia could potentially improve outcomes." | 6.82 | Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. ( Alyea, E; Ballen, KK; Chen, YB; Cutler, C; Dey, BR; Driscoll, J; El-Jawahri, A; Ho, VT; Hunnewell, C; Li, S; McAfee, SL; Poliquin, C; Saylor, M; Soiffer, RJ; Spitzer, TR, 2016) |
| "Busulfan-treated patients had an increased risk of veno-occlusive disease (VOD) of the liver (12% v 1%, P =." | 6.69 | Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplanta ( Jacobsen, N; Lenhoff, S; Ljungman, P; Mellander, L; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1999) |
| " For graft-versus-host disease (GVHD) prophylaxis, cyclosporine and methotrexate were administered." | 5.24 | Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission. ( Baek, S; Choi, EJ; Choi, Y; Jeon, M; Jo, JC; Joo, YD; Kang, YA; Kang, YL; Kim, DY; Kim, H; Kim, SH; Ko, SH; Lee, JH; Lee, KH; Lee, YS; Lim, SN; Park, HS; Seol, M; Yun, SC, 2017) |
| "Fifty patients with high-risk hematologic malignancies, underwent an unmanipulated haploidentical bone marrow transplantation (BMT), followed by posttransplantation high-dose cyclophosphamide (PT-CY): the myeloablative (MA) conditioning consisted of thiotepa, busulfan, fludarabine (n = 35), or total body irradiation (TBI), fludarabine (n = 15)." | 5.17 | Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. ( Bacigalupo, A; Ballerini, F; Bregante, S; Di Grazia, C; Dominietto, A; Geroldi, S; Ghiso, A; Gualandi, F; Lamparelli, T; Luchetti, S; Miglino, M; Raiola, AM; Van Lint, MT; Varaldo, R, 2013) |
| "To reduce the incidence of graft-versus-host disease (GVHD), we added Thymoglobulin (THY) to dose-adjusted oral busulfan plus cyclophosphamide (targeted BUCY)." | 5.12 | Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. ( Anasetti, C; Appelbaum, FR; Boeckh, M; Deeg, HJ; Doney, KC; Flowers, ME; Hansen, JA; Heimfeld, S; Kiem, HP; Martin, PJ; McCune, JS; Myerson, D; Nash, RA; O'Donnell, PV; Radich, JP; Sandmaier, BM; Scott, BL; Sorror, ML; Storb, R; Storer, BE; Warren, EH; Witherspoon, RP; Woolfrey, A, 2006) |
| "We have reported a lower incidence of acute graft-versus-host disease (aGVHD) with a novel conditioning regimen using low-dose rabbit antithymocyte globulin (ATG; Thymoglobulin [TG]) with fludarabine and intravenous busulfan (FluBuTG)." | 3.74 | Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. ( Agovi, MA; Bacigalupo, A; Bahlis, NJ; Ballen, K; Bredeson, CN; Brown, C; Chaudhry, MA; Horowitz, MM; Kurian, S; Muehlenbien, CE; Quinlan, D; Rizzo, JD; Russell, JA; Savoie, L; Stewart, DA; Zhang, MJ, 2008) |
| " In this report, we analyzed the outcome of 101 high-risk patients (70 hematologic and 31 nonhematologic malignancies) who received an HLA-identical sibling allo-SCT after RIC, including fludarabine, busulfan, and antithymocyte globulin (ATG)." | 3.72 | Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. ( Bay, JO; Bilger, K; Blaise, D; Chabannon, C; Choufi, B; Coso, D; Faucher, C; Maraninchi, D; Mohty, M; Stoppa, AM; Tournilhac, O; Vey, N; Viens, P, 2003) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 3.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| " Graft-versus-host disease (GVHD) prophylaxis was attempted with cyclosporine A (CYA) and methotrexate." | 3.70 | [Severe hepatic veno-occlusive disease (VOD) which was successfully treated with supportive therapy, but subsequently developed late-recurrence]. ( Hirabayashi, N; Ikeda, Y; Ishida, A; Matsuoka, S; Moriki, T; Okamoto, S; Wakui, M; Watanabe, R, 1998) |
| " We reviewed our experience using busulfan and cyclophosphamide (CY), instead of TBI, as the preparative regimen for allogeneic BMT to study the incidence and relationship to graft-versus-host disease (GVHD) of post-treatment eosinophilia." | 3.69 | Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen. ( Bolwell, BJ; Kalaycioglu, ME, 1994) |
| "Clofarabine has potent antileukemia activity and its inclusion in reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT) for acute leukemia could potentially improve outcomes." | 2.82 | Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. ( Alyea, E; Ballen, KK; Chen, YB; Cutler, C; Dey, BR; Driscoll, J; El-Jawahri, A; Ho, VT; Hunnewell, C; Li, S; McAfee, SL; Poliquin, C; Saylor, M; Soiffer, RJ; Spitzer, TR, 2016) |
| " In summary, the combination of treosulfan and fludarabine is a safe and efficient conditioning regimen." | 2.71 | Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. ( Casper, J; Dölken, G; Freund, M; Hammer, U; Hartung, G; Kiefer, T; Kleine, HD; Knauf, W; Knopp, A; Steiner, B; Wegener, R; Wilhelm, S; Wolff, D, 2004) |
| "Busulfan-treated patients had an increased risk of veno-occlusive disease (VOD) of the liver (12% v 1%, P =." | 2.69 | Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplanta ( Jacobsen, N; Lenhoff, S; Ljungman, P; Mellander, L; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1999) |
| "Development of myelofibrosis in IMF is obviously due to disease progression unrelated to stage at diagnosis and not significantly influenced by treatment modalities." | 2.42 | Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis. ( Diehl, V; Hülsemann, R; Kvasnicka, HM; Schmitt-Gräff, A; Thiele, J, 2004) |
| "Chronic granulocytic leukemia, chronic lymphocytic leukemia and its variants, and hairy cell leukemia are characterized by prominent organ infiltration and marrow replacement, with a course consisting of years." | 2.36 | The chronic leukemias. ( Liepman, MK, 1980) |
| "The most common primary cancer was acute lymphoblastic leukemia (22 patients, 31." | 1.56 | Factors predicting endocrine late effects in childhood cancer survivors from a Japanese hospital. ( Kazukawa, I; Kihara, M; Minagawa, M; Mori, K; Shimazaki, S, 2020) |
| "Hydroxyurea and myelosan were mostly used as cytostatic drugs while erythrocyte mass transfusions and hemoexfusions (phlebotomy)--for life-support." | 1.32 | [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases]. ( Pop, VP; Rukavitsyn, OA; Seriakov, AP, 2004) |
| "Dyskeratosis congenita is recognized by its dermal lesions and constitutional aplastic anemia in some cases." | 1.30 | Correction of bone marrow failure in dyskeratosis congenita by bone marrow transplantation. ( Alimoghadam, K; Ghahremani, G; Ghavamzadeh, A; Jahani, M; Khodabandeh, A; Nasseri, P, 1999) |
| "Philadelphia chromosome-positive chronic myelogenous leukemia was diagnosed in a now 37-year old woman 16 years ago." | 1.30 | Chronic myelogenous leukemia in chronic phase for 16 years: ongoing hematological remission and late minor cytogenetic response under minimal interferon maintenance therapy. ( Fiegl, M; Jäger, U; Mitterbauer, G; Pirc-Danoewinata, H; Weltermann, A, 1999) |
| " Thus, targeting avoided much of the variability in BU Css seen in other studies and appears to have allowed for an increase in oral dosing from 8 mg/kg to 10." | 1.29 | Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. ( Appelbaum, FR; Bensinger, WI; Buckner, CD; Clift, R; Demirer, T; Fefer, A; Lambert, K; Sanders, J; Slattery, JT; Storb, R, 1996) |
| "Cancrum oris is predominantly seen in children in underdeveloped countries where widespread malnutrition, dehydration and epidemic infections are present." | 1.28 | Cancrum oris-like lesions. ( Cheng, LH; Nash, ES; Smart, K, 1991) |
| "Busulfan was stopped, and only supportive treatment was given." | 1.27 | Busulfan-induced sideroblastic anemia. ( Fernandez, LA; Zayed, E, 1988) |
| "When busulfan treatment was resumed, hematologic response and decrease of hepatomegaly and splenomegaly reoccurred." | 1.27 | Remission of chronic idiopathic myelofibrosis to busulfan treatment. ( Chang, JC; Gross, HM, 1988) |
| "A case of typical idiopathic myelofibrosis turning into polycythaemia vera 6 years after diagnosis is reported." | 1.27 | [Development of polycythemia vera during chronic idiopathic myelofibrosis]. ( Covaz, E; Mazzanti, G; Paladini, G; Tosato, F, 1985) |
| "Chronic granulocytic leukemia developed in a 59-year-old woman who had previously received a total of 21 mCi -32P for polycythemia vera." | 1.25 | Polycythemia vera treated with -32p and myleran: development of chronic granulocytic leukemia with chromosomal abnormalities in one patient. ( Sandnes, K; Staven, P; VAN DER Hagen, CB; Vogt, E, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 46 (44.23) | 18.7374 |
| 1990's | 16 (15.38) | 18.2507 |
| 2000's | 20 (19.23) | 29.6817 |
| 2010's | 18 (17.31) | 24.3611 |
| 2020's | 4 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Xuan, L | 1 |
| Dai, M | 1 |
| Jiang, E | 1 |
| Wang, Y | 1 |
| Huang, F | 1 |
| Fan, Z | 1 |
| Xu, N | 1 |
| Nie, D | 1 |
| Liang, X | 1 |
| Chen, H | 2 |
| Ye, J | 1 |
| Shi, P | 1 |
| Liu, H | 1 |
| Jin, H | 1 |
| Lin, R | 1 |
| Yan, C | 1 |
| Zhang, Y | 1 |
| Sun, J | 1 |
| Han, M | 1 |
| Liu, Q | 1 |
| Sevrin, F | 1 |
| Kolesnikov-Gauthier, H | 1 |
| Cougnenc, O | 1 |
| Bogart, E | 1 |
| Schleiermacher, G | 1 |
| Courbon, F | 1 |
| Gambart, M | 1 |
| Giraudet, AL | 1 |
| Corradini, N | 1 |
| Badel, JN | 1 |
| Rault, E | 1 |
| Oudoux, A | 1 |
| Deley, MCL | 1 |
| Valteau-Couanet, D | 1 |
| Defachelles, AS | 1 |
| Shimazaki, S | 1 |
| Kazukawa, I | 1 |
| Mori, K | 1 |
| Kihara, M | 1 |
| Minagawa, M | 1 |
| Araqi Houssaini, L | 1 |
| Hali, F | 1 |
| Quessar, A | 1 |
| Marnissi, F | 1 |
| Chiheb, S | 1 |
| Lee, KH | 2 |
| Lee, JH | 4 |
| Kim, DY | 2 |
| Park, HS | 1 |
| Choi, EJ | 1 |
| Ko, SH | 1 |
| Seol, M | 1 |
| Lee, YS | 1 |
| Kang, YA | 1 |
| Jeon, M | 1 |
| Baek, S | 1 |
| Kang, YL | 1 |
| Kim, SH | 2 |
| Yun, SC | 1 |
| Kim, H | 1 |
| Jo, JC | 1 |
| Choi, Y | 1 |
| Joo, YD | 1 |
| Lim, SN | 1 |
| Sun, L | 1 |
| Wang, N | 1 |
| Chen, Y | 1 |
| Tang, L | 1 |
| Xing, C | 1 |
| Lu, N | 1 |
| Shi, Y | 1 |
| Ma, Y | 1 |
| Lin, F | 1 |
| Yu, K | 1 |
| Feng, J | 1 |
| Pagliardini, T | 1 |
| Castagna, L | 3 |
| Harbi, S | 2 |
| Porta, MD | 1 |
| Rey, J | 2 |
| Fürst, S | 3 |
| Bramanti, S | 1 |
| Saillard, C | 2 |
| Legrand, F | 1 |
| Maisano, V | 1 |
| Faucher, C | 4 |
| Granata, A | 3 |
| Hospital, MA | 1 |
| Lining, W | 1 |
| Weiller, PJ | 1 |
| Calmels, B | 2 |
| Charbonnier, A | 2 |
| Lemarie, C | 3 |
| Chabannon, C | 5 |
| Vey, N | 3 |
| Mokart, D | 1 |
| Blaise, D | 5 |
| Devillier, R | 2 |
| Kharfan-Dabaja, MA | 1 |
| Anasetti, C | 2 |
| Fernandez, HF | 1 |
| Perkins, J | 1 |
| Ochoa-Bayona, JL | 1 |
| Pidala, J | 1 |
| Perez, LE | 1 |
| Ayala, E | 1 |
| Field, T | 1 |
| Alsina, M | 1 |
| Nishihori, T | 1 |
| Locke, F | 1 |
| Pinilla-Ibarz, J | 1 |
| Tomblyn, M | 1 |
| Crocchiolo, R | 2 |
| El-Cheikh, J | 2 |
| Signori, A | 1 |
| Oudin, C | 2 |
| Mohty, B | 1 |
| Bouabdallah, R | 1 |
| Stoppa, AM | 2 |
| Broussais-Guillaumot, F | 1 |
| Abedin, S | 1 |
| Peres, E | 1 |
| Levine, JE | 1 |
| Choi, S | 1 |
| Yanik, G | 1 |
| Couriel, DR | 1 |
| Shin, SH | 1 |
| Kim, JH | 1 |
| Jeon, YW | 1 |
| Yoon, JH | 1 |
| Yahng, SA | 1 |
| Lee, SE | 1 |
| Choi, YS | 1 |
| Lee, S | 2 |
| Kim, HJ | 3 |
| Min, CK | 2 |
| Lee, JW | 2 |
| Min, WS | 2 |
| Kim, YJ | 2 |
| Aldenhoven, M | 1 |
| Jones, SA | 1 |
| Bonney, D | 1 |
| Borrill, RE | 1 |
| Coussons, M | 1 |
| Mercer, J | 1 |
| Bierings, MB | 1 |
| Versluys, B | 1 |
| van Hasselt, PM | 1 |
| Wijburg, FA | 1 |
| van der Ploeg, AT | 1 |
| Wynn, RF | 1 |
| Boelens, JJ | 1 |
| Piñana, JL | 2 |
| Sanz, J | 1 |
| Esquirol, A | 1 |
| Martino, R | 2 |
| Picardi, A | 1 |
| Barba, P | 1 |
| Parody, R | 1 |
| Gayoso, J | 1 |
| Montesinos, P | 1 |
| Guidi, S | 1 |
| Terol, MJ | 1 |
| Moscardó, F | 1 |
| Solano, C | 1 |
| Arcese, W | 1 |
| Sanz, MA | 1 |
| Sierra, J | 2 |
| Sanz, G | 1 |
| El-Jawahri, A | 1 |
| Li, S | 1 |
| Ballen, KK | 1 |
| Cutler, C | 1 |
| Dey, BR | 1 |
| Driscoll, J | 1 |
| Hunnewell, C | 1 |
| Ho, VT | 1 |
| McAfee, SL | 1 |
| Poliquin, C | 1 |
| Saylor, M | 1 |
| Soiffer, RJ | 1 |
| Spitzer, TR | 1 |
| Alyea, E | 1 |
| Chen, YB | 1 |
| Ravinet, A | 1 |
| Cabrespine, A | 1 |
| Socié, G | 1 |
| Milpied, N | 1 |
| Yakoub Agha, I | 1 |
| Nguyen, S | 1 |
| Michallet, M | 2 |
| Menard, AL | 1 |
| Maillard, N | 1 |
| Mohty, M | 3 |
| Suarez, F | 1 |
| Huynh, A | 1 |
| Marchand, T | 1 |
| Deteix, C | 1 |
| Cassuto, JP | 1 |
| Maury, S | 1 |
| Chevallier, P | 1 |
| Reman, O | 1 |
| Peffault de Latour, R | 1 |
| Bay, JO | 3 |
| Fuji, S | 1 |
| Kim, SW | 1 |
| Yano, S | 1 |
| Hagiwara, S | 1 |
| Nakamae, H | 1 |
| Hidaka, M | 1 |
| Ito, T | 1 |
| Ohashi, K | 1 |
| Hatanaka, K | 1 |
| Takami, A | 1 |
| Kurosawa, S | 1 |
| Yamashita, T | 1 |
| Yamaguchi, T | 1 |
| Fukuda, T | 2 |
| Jaiswal, SR | 1 |
| Chakrabarti, A | 1 |
| Chatterjee, S | 1 |
| Bhargava, S | 1 |
| Ray, K | 1 |
| O'Donnell, P | 1 |
| Chakrabarti, S | 1 |
| Ji, YS | 1 |
| Lee, MS | 1 |
| Min, CW | 1 |
| Park, SK | 1 |
| Yun, J | 1 |
| Kim, KH | 1 |
| Kim, CK | 1 |
| Lee, KT | 1 |
| Won, JH | 1 |
| Hong, DS | 1 |
| Bredeson, CN | 1 |
| Zhang, MJ | 2 |
| Agovi, MA | 1 |
| Bacigalupo, A | 2 |
| Bahlis, NJ | 1 |
| Ballen, K | 1 |
| Brown, C | 1 |
| Chaudhry, MA | 1 |
| Horowitz, MM | 1 |
| Kurian, S | 1 |
| Quinlan, D | 1 |
| Muehlenbien, CE | 1 |
| Russell, JA | 1 |
| Savoie, L | 1 |
| Rizzo, JD | 1 |
| Stewart, DA | 1 |
| Au, BK | 1 |
| Au, MA | 1 |
| Chien, JW | 1 |
| Law, J | 1 |
| Cowan, MJ | 1 |
| Dvorak, CC | 1 |
| Musick, L | 1 |
| Long-Boyle, JR | 1 |
| Baxter-Lowe, LA | 1 |
| Horn, B | 1 |
| Raiola, AM | 1 |
| Dominietto, A | 1 |
| Ghiso, A | 1 |
| Di Grazia, C | 1 |
| Lamparelli, T | 1 |
| Gualandi, F | 1 |
| Bregante, S | 1 |
| Van Lint, MT | 1 |
| Geroldi, S | 1 |
| Luchetti, S | 1 |
| Ballerini, F | 1 |
| Miglino, M | 1 |
| Varaldo, R | 1 |
| Shirasugi, N | 1 |
| Adams, AB | 1 |
| Durham, MM | 1 |
| Lukacher, AE | 1 |
| Xu, H | 1 |
| Rees, P | 1 |
| Cowan, SR | 1 |
| Williams, MA | 1 |
| Pearson, TC | 1 |
| Larsen, CP | 1 |
| Buhr, T | 1 |
| Büsche, G | 1 |
| Choritz, H | 1 |
| Länger, F | 1 |
| Kreipe, H | 1 |
| Choufi, B | 2 |
| Bilger, K | 2 |
| Tournilhac, O | 1 |
| Coso, D | 1 |
| Viens, P | 2 |
| Maraninchi, D | 2 |
| Mineishi, S | 1 |
| Kanda, Y | 1 |
| Saito, T | 1 |
| Nakai, K | 1 |
| Makimoto, A | 1 |
| Kami, M | 1 |
| Tanosaki, R | 2 |
| Wakasugi, H | 1 |
| Tobinai, K | 2 |
| Takaue, Y | 2 |
| Kröger, N | 2 |
| Einsele, H | 1 |
| Wolff, D | 2 |
| Casper, J | 2 |
| Freund, M | 2 |
| Derigs, G | 1 |
| Wandt, H | 1 |
| Schäfer-Eckart, K | 1 |
| Wittkowsky, G | 1 |
| Schmitz, N | 1 |
| Krüger, W | 1 |
| Zabelina, T | 2 |
| Renges, H | 1 |
| Ayuk, F | 1 |
| Krüll, A | 1 |
| Zander, A | 2 |
| Boiron, JM | 1 |
| Cahn, JY | 1 |
| Gratecos, N | 1 |
| Sotto, JJ | 1 |
| François, S | 1 |
| Fleury, J | 1 |
| Gravis, G | 1 |
| Viret, F | 1 |
| Braud, AC | 1 |
| Bardou, VJ | 1 |
| Knauf, W | 1 |
| Kiefer, T | 1 |
| Steiner, B | 1 |
| Hammer, U | 1 |
| Wegener, R | 1 |
| Kleine, HD | 1 |
| Wilhelm, S | 1 |
| Knopp, A | 1 |
| Hartung, G | 1 |
| Dölken, G | 1 |
| Nielsen, I | 1 |
| Hasselbalch, HC | 1 |
| JOSEPHSEN, JO | 2 |
| KLIMA, R | 1 |
| BEYREDER, J | 1 |
| HERZOG, E | 1 |
| SHERMAN, SI | 2 |
| KUZ'MIN, DS | 2 |
| ROZANOVA, LM | 2 |
| KISELEVA, AN | 2 |
| POVERGO, NS | 2 |
| VAKULENKO, AD | 2 |
| DUHAMEL, G | 1 |
| Thiele, J | 1 |
| Kvasnicka, HM | 1 |
| Schmitt-Gräff, A | 1 |
| Hülsemann, R | 1 |
| Diehl, V | 1 |
| Schetelig, J | 1 |
| Bornhäuser, M | 2 |
| Kiehl, M | 1 |
| Schwerdtfeger, R | 1 |
| Runde, V | 1 |
| Held, TK | 1 |
| Thiede, C | 2 |
| Fauser, AA | 1 |
| Beelen, D | 1 |
| Ehninger, G | 2 |
| Siegert, W | 1 |
| Rukavitsyn, OA | 1 |
| Pop, VP | 1 |
| Seriakov, AP | 1 |
| Lu, DP | 1 |
| Dong, L | 1 |
| Wu, T | 1 |
| Huang, XJ | 1 |
| Han, W | 1 |
| Liu, DH | 1 |
| Gao, ZY | 1 |
| Chen, YH | 1 |
| Xu, LP | 1 |
| Zhang, YC | 1 |
| Ren, HY | 1 |
| Li, D | 1 |
| Liu, KY | 1 |
| Deeg, HJ | 1 |
| Storer, BE | 1 |
| Boeckh, M | 1 |
| Martin, PJ | 1 |
| McCune, JS | 1 |
| Myerson, D | 1 |
| Heimfeld, S | 1 |
| Flowers, ME | 1 |
| Doney, KC | 1 |
| Hansen, JA | 1 |
| Kiem, HP | 1 |
| Nash, RA | 1 |
| O'Donnell, PV | 1 |
| Radich, JP | 1 |
| Sandmaier, BM | 1 |
| Scott, BL | 1 |
| Sorror, ML | 1 |
| Warren, EH | 1 |
| Witherspoon, RP | 1 |
| Woolfrey, A | 1 |
| Appelbaum, FR | 2 |
| Storb, R | 2 |
| Cho, BS | 1 |
| Cho, SG | 1 |
| Kim, SY | 1 |
| Eom, KS | 1 |
| Kim, DW | 1 |
| Kim, CC | 1 |
| Valcárcel, D | 1 |
| Caballero, D | 1 |
| Martin, J | 1 |
| Ferra, C | 1 |
| Nieto, JB | 1 |
| Sampol, A | 1 |
| Bernal, MT | 1 |
| Vazquez, L | 1 |
| Ribera, JM | 1 |
| Besalduch, J | 1 |
| Moraleda, JM | 1 |
| Carrera, D | 1 |
| Brunet, MS | 1 |
| Perez-Simón, JA | 1 |
| Yamasaki, S | 1 |
| Heike, Y | 1 |
| Mori, S | 1 |
| Maruyama, D | 1 |
| Kato, R | 1 |
| Usui, E | 1 |
| Koido, K | 1 |
| Kim, S | 1 |
| Teshima, T | 1 |
| Molyneux, G | 1 |
| Gibson, FM | 1 |
| Whayman, M | 1 |
| Turton, JA | 1 |
| Advani, SH | 1 |
| Dinshaw, KA | 1 |
| Nair, CN | 1 |
| Ramakrishnan, G | 1 |
| Phillips, GL | 2 |
| Herzig, GP | 1 |
| Beschorner, WE | 1 |
| Padmanabhan, K | 1 |
| Subramanian, R | 1 |
| Vaidyanathan, CV | 1 |
| Liepman, MK | 1 |
| Woodruff, RK | 1 |
| Ljungman, P | 2 |
| Hassan, M | 1 |
| Békássy, AN | 1 |
| Ringdén, O | 2 |
| Oberg, G | 1 |
| Ohnishi, K | 1 |
| Ohno, R | 1 |
| Tomonaga, M | 1 |
| Kamada, N | 1 |
| Onozawa, K | 1 |
| Kuramoto, A | 1 |
| Dohy, H | 1 |
| Mizoguchi, H | 1 |
| Miyawaki, S | 1 |
| Tsubaki, K | 1 |
| Kalaycioglu, ME | 1 |
| Bolwell, BJ | 1 |
| Xun, CQ | 1 |
| Thompson, JS | 1 |
| Jennings, CD | 1 |
| Brown, SA | 1 |
| Widmer, MB | 1 |
| Vowels, M | 1 |
| Chan, LL | 1 |
| Giri, N | 1 |
| Russell, S | 1 |
| Lam-Po-Tang, R | 1 |
| von Bueltzingsloewen, A | 1 |
| Belanger, R | 1 |
| Perreault, C | 1 |
| Bonny, Y | 1 |
| Roy, DC | 1 |
| Lalonde, Y | 1 |
| Boileau, J | 1 |
| Kassis, J | 1 |
| Lavallee, R | 1 |
| Lacombe, M | 1 |
| Tura, S | 1 |
| Demirer, T | 1 |
| Buckner, CD | 1 |
| Bensinger, WI | 1 |
| Sanders, J | 1 |
| Lambert, K | 1 |
| Clift, R | 1 |
| Fefer, A | 1 |
| Slattery, JT | 1 |
| Arslan, O | 1 |
| Akan, H | 1 |
| Koç, H | 1 |
| Beksaç, M | 1 |
| Ilhan, O | 1 |
| Ozcan, M | 1 |
| Yalçín, S | 1 |
| Gürman, G | 1 |
| Konuk, N | 1 |
| Uysal, A | 1 |
| Khoroshko, ND | 1 |
| Turkina, AG | 1 |
| Zhuravlev, VS | 1 |
| Sokolova, MA | 1 |
| Mikhaĭlova, IN | 1 |
| Zakharova, AV | 1 |
| Domracheva, EV | 1 |
| Semenova, EA | 1 |
| Matsuoka, S | 1 |
| Okamoto, S | 1 |
| Ishida, A | 1 |
| Wakui, M | 1 |
| Watanabe, R | 1 |
| Moriki, T | 1 |
| Ikeda, Y | 1 |
| Hirabayashi, N | 1 |
| Ghavamzadeh, A | 1 |
| Alimoghadam, K | 1 |
| Nasseri, P | 1 |
| Jahani, M | 1 |
| Khodabandeh, A | 1 |
| Ghahremani, G | 1 |
| Remberger, M | 1 |
| Ruutu, T | 1 |
| Nikoskelainen, J | 1 |
| Volin, L | 1 |
| Vindeløv, L | 1 |
| Parkkali, T | 1 |
| Lenhoff, S | 1 |
| Sallerfors, B | 1 |
| Mellander, L | 1 |
| Jacobsen, N | 1 |
| Fiegl, M | 1 |
| Mitterbauer, G | 1 |
| Weltermann, A | 1 |
| Pirc-Danoewinata, H | 1 |
| Jäger, U | 1 |
| Platzbecker, U | 1 |
| Jenke, A | 1 |
| Helwig, A | 1 |
| Plettig, R | 1 |
| Freiberg-Richter, J | 1 |
| Röllig, C | 1 |
| Geissler, G | 1 |
| Lutterbeck, K | 1 |
| Oelschlagel, U | 1 |
| Taketani, T | 1 |
| Kikuchi, A | 1 |
| Inatomi, J | 1 |
| Hanada, R | 1 |
| Kawaguchi, H | 1 |
| Ida, K | 1 |
| Oh-Ishi, T | 1 |
| Arai, T | 1 |
| Kishimoto, H | 1 |
| Yamamoto, K | 1 |
| Atanasov, K | 1 |
| Baltov, I | 1 |
| Kirova, V | 1 |
| Vakrilov, V | 1 |
| Tzvetkova, T | 1 |
| Das, KV | 1 |
| Thomas, M | 1 |
| Pilla, MV | 1 |
| Pugsley, CA | 1 |
| Forbes, IJ | 1 |
| Morley, AA | 2 |
| Trainor, KJ | 1 |
| Seshadri, RS | 1 |
| Spiers, AS | 4 |
| Whittaker, JA | 2 |
| Khurshid, M | 2 |
| Staven, P | 1 |
| VAN DER Hagen, CB | 1 |
| Vogt, E | 1 |
| Sandnes, K | 1 |
| Liew, A | 1 |
| Baikie, AG | 2 |
| Barikie, AG | 1 |
| Bartnall, JA | 1 |
| Cox, JI | 1 |
| Jacobs, P | 1 |
| Dubovsky, D | 1 |
| King, H | 1 |
| Sealy, R | 1 |
| Gunz, FW | 1 |
| Nevill, TJ | 1 |
| Shepherd, JD | 1 |
| Reece, DE | 1 |
| Barnett, MJ | 1 |
| Nantel, SH | 1 |
| Klingemann, HG | 1 |
| Nash, ES | 1 |
| Cheng, LH | 1 |
| Smart, K | 1 |
| Brito-Babapulle, F | 1 |
| Bowcock, SJ | 1 |
| Marcus, RE | 1 |
| Apperley, J | 1 |
| Th'ng, KH | 1 |
| Dowding, C | 1 |
| Rassool, F | 1 |
| Guo, AP | 1 |
| Catovsky, D | 1 |
| Galton, DA | 1 |
| Manoharan, A | 1 |
| Fernandez, LA | 1 |
| Zayed, E | 1 |
| Chang, JC | 1 |
| Gross, HM | 1 |
| Paladini, G | 1 |
| Tosato, F | 1 |
| Mazzanti, G | 1 |
| Covaz, E | 1 |
| Thompson, EN | 1 |
| Soothill, JF | 1 |
| Resnick, M | 1 |
| Myerson, RM | 1 |
| Rorvik, TO | 1 |
| Pietschmann, H | 1 |
| Kolarz, G | 2 |
| Prandota, J | 1 |
| Hunstein, W | 1 |
| Hughes, HR | 1 |
| Salmon, M | 1 |
| Orsini, A | 1 |
| Giraud, F | 1 |
| Perrimond, H | 1 |
| Gonggryp, N | 1 |
| Markum, AH | 1 |
| Abdulsalam, M | 1 |
| Muslichan, S | 1 |
| Iskandar, W | 1 |
| Hoshino, A | 1 |
| Gibson, OM | 1 |
| Burgess, MA | 1 |
| Stanley, LG | 1 |
| Koza, I | 1 |
| Cerný, V | 1 |
| Bohunický, L | 1 |
| Hal'ko, J | 1 |
| Ujházy, V | 1 |
| Petrek, C | 1 |
| Krizan, Z | 1 |
| Olesen, J | 1 |
| Videbaek, A | 1 |
| Brichta, G | 1 |
| Reimer, EE | 1 |
| Stoiber, T | 1 |
| Pietsehmann, H | 1 |
| Regele, H | 1 |
| Marcovitch, H | 1 |
| Morowitz, DA | 1 |
| Allen, LW | 1 |
| Kirsner, JB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial of Haploidentical Natural Killer (NK) Cells in Combination With Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)[NCT03366064] | Phase 1 | 5 participants (Actual) | Interventional | 2017-11-09 | Completed | ||
| Allogeneic HCT From Donor-sources of Matched-sibling, Matched-unrelated, or Haploidentical-family Donors Using Uniform Conditioning Regimen of Busulfan, Fludarabine, and Antithymocyte Globulin for AML in Remission - an Observational Study[NCT03337568] | 110 participants (Anticipated) | Observational | 2017-04-01 | Recruiting | |||
| Trial Of Double Umbilical Cord Blood Transplantation[NCT00763490] | Phase 2 | 20 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| The Use of Granulocyte Transfusions After Umbilical Cord Blood Transplant for Leukaemia: A Prospective, Non-randomised, Single-centre Study to Evaluate Safety and Immune Reconstitution[NCT05425043] | 20 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | |||
| Phase I/II Study Evaluating Safety and Efficacy of Autologous Hematopoietic Stem and Progenitor Cells Genetically Modified With IDUA Lentiviral Vector Encoding for the Human α-L-iduronidase Gene for the Treatment of Patients Affected by Mucopolysaccharido[NCT03488394] | Phase 1/Phase 2 | 8 participants (Actual) | Interventional | 2018-05-11 | Active, not recruiting | ||
| PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant[NCT01366612] | Phase 3 | 53 participants (Actual) | Interventional | 2010-06-16 | Terminated (stopped due to Lack of Accrual) | ||
| Bone Marrow Transplantation HLA Haploidentical After a Reduced Intensity Conditioning and Prevention of GvHD Based on Post-transplant Cyclophosphamide Administration in Patients With Severe Sickle Cell Disease[NCT03240731] | Phase 2 | 18 participants (Anticipated) | Interventional | 2017-08-10 | Active, not recruiting | ||
| Allogeneic Stem Cell Transplantation With Alternative Donor in Treatment of Hematologic Malignancy[NCT02487069] | 876 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| Single Arm, Open Label, Phase I Study for Dose and Schedule Finding of Decitabine in Patients With Higher-risk MDS and MDS/AML Receiving Allogeneic Stem Cell Transplantation[NCT01277484] | Phase 1 | 19 participants (Actual) | Interventional | 2011-01-31 | Active, not recruiting | ||
| Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Chronic Phase CML[NCT00001144] | Phase 2 | 50 participants | Interventional | 1999-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
One-year survival rate after transplant (NCT00763490)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Double Cord Blood Tranplant | 40 |
Event Free Survival (EFS) was determined. Patients were followed up to 5 years (median time of 2.35 years). (NCT00763490)
Timeframe: 5 Years
| Intervention | percentage of patients (Number) |
|---|---|
| Double Cord Blood Tranplant | 35 |
The failure to achieve a neutrophil count > 500/uL or a platelet count >30.0 x 10e9 /L within 35 days of the stem cell infusion will be defined as primary engraftment failure. (NCT00763490)
Timeframe: Day 35
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Cumulative incidence of platlet engraftment | Cumulative incidence of neutrophil engraftment | |
| Double Cord Blood Tranplant | 73 | 89 |
"The percentage of patients with acute GVHD (Grade II-IV) was determined at 100 days. Patients were followed up to 5 years and the percentage of patients that developed chronic GVHD at the end of the study was tabulated.~Acute GVHD is staged and graded (grade 0-IV, where grade 0 is no involvement and involvement increases by grade) by the number and extent of organ involvement. Patients can have involvement of three organs: skin (rash/dermatitis), liver (hepatitis/jaundice), and gastrointestinal tract (abdominal pain/diarrhea)." (NCT00763490)
Timeframe: Up to 5 years
| Intervention | percentage of patients (Number) | |
|---|---|---|
| Acute GVHD (Grades II-IV) | Chronic GVHD | |
| Double Cord Blood Tranplant | 40 | 35 |
(NCT01366612)
Timeframe: 1 year
| Intervention | Percent (Number) |
|---|---|
| Group 1 | 38.9 |
| Group 2 | 18.8 |
8 reviews available for busulfan and Chronic Disease
| Article | Year |
|---|---|
Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Bone Marrow; Busulfan; Ch | 2004 |
Destruction of the intestinal mucosa after bone marrow transplantation and graft-versus-host disease.
Topics: Acute Disease; Bone Marrow Transplantation; Busulfan; Chronic Disease; Combined Modality Therapy; Cy | 1984 |
The chronic leukemias.
Topics: Adult; Busulfan; Chromosomes, Human, 21-22 and Y; Chronic Disease; Humans; Leukemia; Leukemia, Hairy | 1980 |
Chronic myeloid leukaemia.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Busulfan; Cell Transformation, Neoplastic; Child, | 1981 |
The management of elderly patients with myeloproliferative disorders.
Topics: Adult; Age Factors; Aged; Bone Marrow Transplantation; Busulfan; Chronic Disease; Humans; Hydroxyure | 1993 |
The treatment of chronic granulocytic leukaemia.
Topics: Adult; Blood Transfusion; Busulfan; Cell Transformation, Neoplastic; Chronic Disease; Humans; Immuno | 1976 |
[Chemotherapy of chronic leukemias].
Topics: Antineoplastic Agents; Busulfan; Chlorambucil; Chronic Disease; Cyclophosphamide; Humans; Hydroxyure | 1974 |
[Therapeutic considerations in chronic myeloid leukemia].
Topics: Busulfan; Chronic Disease; Cytarabine; Humans; Hydrocarbons, Brominated; Leukemia, Myeloid; Mannitol | 1974 |
20 trials available for busulfan and Chronic Disease
| Article | Year |
|---|---|
The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodyspl
Topics: Anemia, Refractory, with Excess of Blasts; Busulfan; Chronic Disease; Cyclophosphamide; Decitabine; | 2023 |
Phase II study of
Topics: 3-Iodobenzylguanidine; Adolescent; Busulfan; Child; Child, Preschool; Chronic Disease; Humans; Melph | 2023 |
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosph | 2017 |
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosph | 2017 |
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosph | 2017 |
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosph | 2017 |
Unrelated Donor Peripheral Blood Stem Cell Transplantation for Patients with β-Thalassemia Major Based on a Novel Conditioning Regimen.
Topics: Acute Disease; Adult; Allografts; Antilymphocyte Serum; beta-Thalassemia; Busulfan; Child; Child, Pr | 2019 |
Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.
Topics: Adult; Aged; Allografts; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; | 2019 |
Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Busulfan; CD4 Lymphocyte Count; CD4-Positive T-Ly | 2013 |
Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blo | 2014 |
Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Cord Blood Stem Cell Transpla | 2016 |
Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia.
Topics: Adenine Nucleotides; Adult; Aged; Arabinonucleosides; Busulfan; Chronic Disease; Clofarabine; Female | 2016 |
A prospective multicenter study of unrelated bone marrow transplants using a reduced-intensity conditioning regimen with low-dose ATG-F.
Topics: Adult; Aged; Allografts; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Diseas | 2016 |
Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-, Busulfan-, and Melphalan-Based Conditioning.
Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Chronic Disease; Cy | 2016 |
Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Busulfan; Child; Child, P | 2012 |
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan | 2013 |
Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Fre | 2003 |
Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Busulfan; Chronic Disease; Family; Female; Histocompa | 2004 |
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Cause of Death; Child; Chron | 2006 |
The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome.
Topics: Adolescent; Adult; Antineoplastic Agents; Busulfan; Chronic Disease; Female; Follow-Up Studies; Graf | 2007 |
A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase.
Topics: Adult; Blood Cell Count; Bone Marrow; Busulfan; Chronic Disease; Female; Humans; Interferon-alpha; L | 1995 |
Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplanta
Topics: Adolescent; Adult; Alopecia; Bone Marrow Transplantation; Bronchiolitis Obliterans; Busulfan; Catara | 1999 |
Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy P | 2001 |
76 other studies available for busulfan and Chronic Disease
| Article | Year |
|---|---|
Factors predicting endocrine late effects in childhood cancer survivors from a Japanese hospital.
Topics: Adolescent; Adult; Antineoplastic Agents; Brain Neoplasms; Busulfan; Cancer Survivors; Child; Chroni | 2020 |
[Cutaneous complications following hematopoietic stem cell transplantation].
Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Candidiasis; Chickenpox; Child; Chronic Dise | 2021 |
National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busul | 2014 |
Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Chronic Disease; Female; Graft v | 2014 |
Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Female; Graft vs Host D | 2015 |
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantat | 2015 |
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantat | 2015 |
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantat | 2015 |
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantat | 2015 |
Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulair
Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chi-Square Distribut | 2016 |
Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease-Free Survival; Drug T | 2016 |
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Chro | 2008 |
Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Bronchiolitis Obliterans; Busulfan; Chronic Di | 2011 |
Prevention of chronic rejection in murine cardiac allografts: a comparison of chimerism- and nonchimerism-inducing costimulation blockade-based tolerance induction regimens.
Topics: Acute Disease; Animals; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Chronic Disease; C | 2002 |
Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Chroni | 2003 |
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease Progressi | 2003 |
Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Chronic Disease; Cladribine; Cyclophosphamide; Dis | 2003 |
Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Disease; | 2004 |
Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Topics: Acute Disease; Alkylating Agents; Busulfan; Chronic Disease; Drug Therapy, Combination; Female; Huma | 2003 |
[Myleran in chronic myelogenic leukemia].
Topics: Busulfan; Chronic Disease; Humans; Leukemia; Leukemia, Myeloid | 1956 |
[Myleran in chronic myelogenic leukemia].
Topics: Busulfan; Chronic Disease; Humans; Leukemia; Leukemia, Myeloid | 1956 |
[Myleran in chronic myelogenic leukemia].
Topics: Busulfan; Chronic Disease; Humans; Leukemia; Leukemia, Myeloid | 1956 |
[Myleran in chronic myelogenic leukemia].
Topics: Busulfan; Chronic Disease; Humans; Leukemia; Leukemia, Myeloid | 1956 |
[Cytostatic prolonged therapy in chronic leukemia].
Topics: Busulfan; Chronic Disease; Humans; Leukemia; Leukemia, Myeloid | 1957 |
[Comparative evaluation of the effectiveness of certain therapeutic methods in chronic leukemias; roentgen rays, radioactive phosphorus, urethane, embichine, arsenic, myleran. IV].
Topics: Arsenic; Busulfan; Chronic Disease; Leukemia; Phosphorus; Phosphorus, Dietary; Radioactivity; Uretha | 1959 |
[Comparative evaluation of the effectiveness of certain therapeutic methods in chronic leukemias; roentgen rays, radioactive phosphorus, urethane, embichine, arsenic, myleran. V].
Topics: Arsenic; Busulfan; Chronic Disease; Leukemia; Phosphorus; Phosphorus, Dietary; Radioactivity; Uretha | 1959 |
[CHRONIC LEUKEMIA. RECENT DATA ON ITS DIAGNOSIS AND TREATMENT].
Topics: Busulfan; Child; Chronic Disease; Leukemia; Leukemia, Myeloid; Neoplasms | 1963 |
Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Combined Modality Thera | 2004 |
[Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; | 2004 |
Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation.
Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protoco | 2006 |
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Topics: Adult; Aged; Busulfan; Chronic Disease; Disease-Free Survival; Drug Therapy, Combination; Female; Gr | 2008 |
Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens.
Topics: Adolescent; Adult; Aged; Aspergillosis; Bacteremia; Busulfan; Catheterization, Central Venous; Chron | 2008 |
Serum FLT-3 ligand in a busulphan-induced model of chronic bone marrow hypoplasia in the female CD-1 mouse.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood Cell Count; Body Weight; Bone Marrow Cells; Bone M | 2008 |
Total body irradiation in chronic myeloid leukemia.
Topics: Adolescent; Adult; Busulfan; Chronic Disease; Female; Humans; Leukemia, Myeloid; Leukocyte Count; Ma | 1983 |
Intensive chemotherapy, total body irradiation, and autologous marrow transplantation for chronic granulocytic leukemia-blast phase: report of four additional cases.
Topics: Adult; Bone Marrow; Bone Marrow Transplantation; Busulfan; Child; Chromosomes, Human, 21-22 and Y; C | 1984 |
Chronic granulocytic leukemia with lymphadenopathy and leukemia cutis.
Topics: Adult; Busulfan; Chronic Disease; Female; Humans; Leukemia, Myeloid; Lymphatic Metastasis; Skin; Ski | 1982 |
Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants.
Topics: Adolescent; Adult; Alopecia; Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Child; Child, | 1995 |
Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Eosinop | 1994 |
Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice.
Topics: Acute Disease; Animals; Busulfan; Cell Transplantation; Chronic Disease; Cyclophosphamide; Cytokines | 1994 |
Factors affecting hair regrowth after bone marrow transplantation.
Topics: Adolescent; Adult; Age Factors; Alopecia; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan | 1993 |
Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies.
Topics: Adult; Busulfan; Chronic Disease; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Female; | 1993 |
Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Busulfan; Child; Child, Preschool; Chronic D | 1996 |
Eosinophilia after allogeneic bone marrow transplantation using busulfan and cyclophosphamide conditioning regimen.
Topics: Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Eosinophilia; Graft vs Hos | 1996 |
[A modern therapeutic strategy in Ph-positive chronic myeloleukemia].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 1996 |
[Severe hepatic veno-occlusive disease (VOD) which was successfully treated with supportive therapy, but subsequently developed late-recurrence].
Topics: Adult; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Cyclosporine; Graft | 1998 |
Correction of bone marrow failure in dyskeratosis congenita by bone marrow transplantation.
Topics: Adolescent; Adult; Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cycloph | 1999 |
Chronic myelogenous leukemia in chronic phase for 16 years: ongoing hematological remission and late minor cytogenetic response under minimal interferon maintenance therapy.
Topics: Adult; Antineoplastic Agents; Busulfan; Chronic Disease; Cytogenetics; Female; Humans; Hydroxyurea; | 1999 |
Chronic active Epstein-Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Chronic Dise | 2002 |
Chronic myelosis treatment with Myleran (Myelosan).
Topics: Adult; Busulfan; Chronic Disease; Female; Humans; Leukemia, Myeloid; Male; Middle Aged | 1978 |
Observations on the therapy of chronic granulocytic leukaemia (C.G.L.) in adults.
Topics: Adolescent; Adult; Aged; Busulfan; Child; Chronic Disease; Female; Humans; India; Leukemia, Myeloid; | 1977 |
Immunologic abnormalities in an animal model of chronic hypoplastic marrow failure induced by busulfan.
Topics: Anemia, Aplastic; Animals; Antibody-Producing Cells; B-Lymphocytes; Blood Cell Count; Busulfan; Chro | 1978 |
Chronic hypoplastic marrow failure and residual injury.
Topics: Anemia, Aplastic; Animals; Bone Marrow; Bone Marrow Transplantation; Busulfan; Cell Division; Chroni | 1978 |
Hypofibrinogenaemia as a cause of bleeding in chronic myeloid leukaemia.
Topics: Afibrinogenemia; Aged; Blood Cell Count; Bone Marrow Cells; Busulfan; Chronic Disease; Disseminated | 1975 |
Polycythemia vera treated with -32p and myleran: development of chronic granulocytic leukemia with chromosomal abnormalities in one patient.
Topics: Anemia, Hemolytic, Autoimmune; Busulfan; Chromosomes, Human, 1-3; Chromosomes, Human, 6-12 and X; Ch | 1975 |
Neutrophil alkaline phosphatase score in chronic granulocytic leukaemia: effects of splenectomy and antileukaemic drugs.
Topics: Alkaline Phosphatase; Bone Marrow Cells; Busulfan; Chronic Disease; Clinical Enzyme Tests; Histocyto | 1975 |
Cytogenetic studies of the spleen in chronic granulocytic leukaemia.
Topics: Adult; Busulfan; Cell Line; Chromosome Aberrations; Chromosomes, Human, 21-22 and Y; Chronic Disease | 1975 |
Splenic irradiation in the management of chronic granulocytic leukaemia.
Topics: Adult; Aged; Busulfan; Chronic Disease; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Radiat | 1975 |
Diagnostic and therapeutic approach to chronic leukaemia.
Topics: Busulfan; Chlorambucil; Chronic Disease; Diagnosis, Differential; Glucocorticoids; Leukemia; Leukemi | 1975 |
Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT.
Topics: Acute Disease; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Trans | 1992 |
Cancrum oris-like lesions.
Topics: Ampicillin; Busulfan; Candida albicans; Chronic Disease; Diagnosis, Differential; Disease Susceptibi | 1991 |
Autografting for patients with chronic myeloid leukaemia in chronic phase: peripheral blood stem cells may have a finite capacity for maintaining haemopoiesis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chronic Disease; Combined Modality | 1989 |
Remission of chronic idiopathic myelofibrosis to busulphan treatment.
Topics: Busulfan; Chronic Disease; Humans; Primary Myelofibrosis | 1989 |
Busulfan-induced sideroblastic anemia.
Topics: Anemia, Sideroblastic; Bone Marrow; Busulfan; Chronic Disease; Cytarabine; Drug Therapy, Combination | 1988 |
Remission of chronic idiopathic myelofibrosis to busulfan treatment.
Topics: Aged; Biopsy; Bone Marrow; Busulfan; Chronic Disease; Drug Evaluation; Female; Humans; Male; Middle | 1988 |
[Development of polycythemia vera during chronic idiopathic myelofibrosis].
Topics: Adult; Anemia, Myelophthisic; Busulfan; Chronic Disease; Hepatomegaly; Humans; Male; Platelet Count; | 1985 |
Chronic granulomatous disease: quantitative clinicopathological relationships.
Topics: Adolescent; Anemia; Arthritis; Blood Proteins; Body Height; Body Weight; Busulfan; Child; Child, Pre | 1970 |
Hypereosinophilic syndrome. Report of two cases, with prolonged courses.
Topics: Adult; Busulfan; Cardiomegaly; Chronic Disease; Cyclophosphamide; Eosinophilia; Eosinophils; Hepatom | 1971 |
Chronic granulocytic leukaemia and chronic lymphocytic leukaemia.
Topics: Allopurinol; Amenorrhea; Busulfan; Chlorambucil; Chronic Disease; Drug Eruptions; Female; Hemolysis; | 1974 |
[Polycythemia vera].
Topics: Busulfan; Chronic Disease; Diagnosis, Differential; Hemorrhage; Humans; Phosphorus Radioisotopes; Po | 1974 |
[Myleran lung in chronic myelosis].
Topics: Busulfan; Carcinoma; Chronic Disease; Diagnosis, Differential; Female; Humans; Leukemia, Myeloid; Lu | 1973 |
Chronic granulocytic leukaemia.
Topics: Adult; Busulfan; Child; Chromosome Aberrations; Chromosomes, Human, 21-22 and Y; Chronic Disease; Di | 1974 |
Neutrophil function in chronic granulocytic leukaemia before and after busulphan treatment.
Topics: Busulfan; Chronic Disease; Humans; Leukemia, Myeloid; Muramidase; Neutrophils; Phagocytosis; Skin Wi | 1974 |
[Antimetabolites and pregnancy. Normal child born to a mother under treatment 8 years for chronic myeloid leukemia].
Topics: Abortion, Therapeutic; Adolescent; Busulfan; Chronic Disease; Female; Humans; Leukemia, Myeloid; Leu | 1972 |
Immunosuppressive agents in the treatment of chronic idiopathic thrombocytopenic purpura.
Topics: Antibodies; Azathioprine; Blood Platelets; Busulfan; Child; Child, Preschool; Chronic Disease; Drug | 1973 |
Mitomycin C in the treatment of chronic myelogenous leukemia.
Topics: Animals; Busulfan; Chronic Disease; Leukemia, Myeloid; Mercaptopurine; Mitomycins; Rats | 1967 |
Cytogenetic remission in acute transformation of chronic granulocytic leukaemia.
Topics: Acute Disease; Aged; Aneuploidy; Bone Marrow Diseases; Busulfan; Cell Transformation, Neoplastic; Ch | 1969 |
Blastic crisis of chronic myelogenous leukaemia.
Topics: Acute Disease; Adult; Antineoplastic Agents; Busulfan; Chronic Disease; Female; Hematopoiesis; Human | 1969 |
[Chronic myelogenous leukemia. Results of therapy with busulfan].
Topics: Adult; Age Factors; Aged; Ambulatory Care; Blood Transfusion; Busulfan; Chronic Disease; Female; Fol | 1969 |
[Chronic myelosis. Clinical picture and therapy].
Topics: Antineoplastic Agents; Busulfan; Chronic Disease; Gold Isotopes; Leukemia, Myeloid; Pipobroman; Sple | 1969 |
[Lung changes under busulfan therapy in a case of chronic myelosis].
Topics: Busulfan; Chronic Disease; Female; Humans; Leukocyte Count; Lung; Lung Diseases; Middle Aged; Primar | 1970 |
Chronic granulomatous disease of childhood.
Topics: Anti-Bacterial Agents; Busulfan; Child; Child, Preschool; Chronic Disease; Coloring Agents; Female; | 1970 |
Thrombocytosis in chronic inflammatory bowel disease.
Topics: Adolescent; Adult; Blood Cell Count; Blood Platelets; Bone Marrow Cells; Busulfan; Chronic Disease; | 1968 |